The sequential use of CPC detection in men with a raised total PSA has shown a high negative predictive value (Murray et al., 2016), and may reduce the number of men undergoing prostate biopsy without missing a significant number of clinically important prostate cancer (Murray et al., 2017). The gene discussed is KLK3; the disease is prostate carcinoma.